Related references
Note: Only part of the references are listed.Fc fusion as a platform technology: potential for modulating immunogenicity
Ditza Levin et al.
TRENDS IN BIOTECHNOLOGY (2015)
Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets
Meena Jhanwar-Uniyal et al.
CANCERS (2015)
Wilms' tumor gene WT1 promotes homologous recombination-mediated DNA damage repair
Yusuke Oji et al.
MOLECULAR CARCINOGENESIS (2015)
A brief history of T cell help to B cells
Shane Crotty
NATURE REVIEWS IMMUNOLOGY (2015)
Wilms Tumor Gene ( WT1) Peptide- based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer
Sumiyuki Nishida et al.
JOURNAL OF IMMUNOTHERAPY (2014)
The Wilms' tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression
Kay-Dietrich Wagner et al.
NATURE COMMUNICATIONS (2014)
Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers
Hidenori Takahashi et al.
EUROPEAN JOURNAL OF CANCER (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody
Tao Dao et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naive T-cell subtypes
Ines Moeller et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Human IgG isotypes and activating Fcγ receptors in the interaction of Salmonella enterica serovar Typhimurium with phagocytic cells
Yun S. Goh et al.
IMMUNOLOGY (2011)
Sensitive immunohistochemical detection of WT1 protein in tumors with anti-WT1 antibody against WT1 235 peptide
Ryo Ichinohasama et al.
CANCER SCIENCE (2010)
WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient
Yusuke Oji et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Control systems and decision making for antibody production
Christopher C. Goodnow et al.
NATURE IMMUNOLOGY (2010)
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
Viggo F. Van Tendeloo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells
Yoriko Saito et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor
Yusuke Oji et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Detection of humoral immune responses against WT1 antigen in patients affected by different hematological malignancies
Paolo Nicoli et al.
ACTA HAEMATOLOGICA (2008)
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
Shuichi Izumoto et al.
JOURNAL OF NEUROSURGERY (2008)
The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo
N. Wagner et al.
ONCOGENE (2008)
Antiapoptotic function of 17AA(+) WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway
K. Ito et al.
ONCOGENE (2006)
Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro
T Jomgeow et al.
CANCER SCIENCE (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies
F Wu et al.
LEUKEMIA (2005)
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
Y Oka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma
Y Oji et al.
CANCER SCIENCE (2004)
Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity
V Mailander et al.
LEUKEMIA (2004)
Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors
Y Oji et al.
CANCER SCIENCE (2004)
Cutting edge:: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells
J Pène et al.
JOURNAL OF IMMUNOLOGY (2004)
Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma
Y Oji et al.
CANCER SCIENCE (2003)
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis
Y Oka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)
Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers
Y Oji et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies
OA Elisseeva et al.
BLOOD (2002)
Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8+ T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay
K Kuzushima et al.
BLOOD (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Cancer immunotherapy targeting Wilms' tumor gene WT1 product
Y Oka et al.
JOURNAL OF IMMUNOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product
Y Oka et al.
IMMUNOGENETICS (2000)
Share Paper
